Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to BTK inhibition, the phase I/II BRUIN study showed. Among 247 patients who had previously received a covalent BTK inhibitor, 73.3% (95% CI 67.3-78.7) achieved an overall […]
Dolutegravir Switch Maintains Second-Line HIV Suppression
Switching people living with HIV from a ritonavir-boosted protease inhibitor (PI) to a dolutegravir (Tivicay)-based regimen maintained viral suppression just as well, according to a randomized trial out of Kenya. Among a cohort of nearly 800 participants, 5.0% who switched to dolutegravir and 5.1% who continued taking a ritonavir-boosted PI had a plasma HIV type […]
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma
CHICAGO — Adding the immune checkpoint inhibitor nivolumab (Opdivo), rather than brentuximab vedotin (Adcetris), to a standard chemotherapy backbone reduced the risk of disease progression or death in newly diagnosed adults and adolescents with advanced-stage classical Hodgkin lymphoma (cHL), according to the SWOG S1826 trial. Patients in the phase III study received six cycles of […]
FDA OKs Olaparib-Abiraterone for Metastatic Prostate Cancer
The FDA has approved the PARP inhibitor olaparib (Lynparza) in combination with abiraterone (Zytiga) for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), the agency announced Wednesday. Adult patients should be selected for the combination therapy — which is given with prednisone (or prednisolone) — based on an FDA-approved companion diagnostic test to detect deleterious or suspected […]
Post-Immunotherapy Combo Promising in Advanced RCC
Combination treatment with a hypoxia-inducible factor (HIF) 2α inhibitor and tyrosine kinase inhibitor induced responses in nearly a third of advanced renal cell carcinoma (RCC) patients previously treated with immunotherapy, a single-arm phase II study found. In the study of 52 patients, 30.8% (95% CI 18.7-45.1) had a confirmed objective response following treatment with belzutifan […]
Combo Falters in Papillary Renal Cancer, but Some Promise in MET-Driven Subset
Treatment with an investigational MET inhibitor plus a PD-L1 inhibitor induced responses in fewer than a third of patients with metastatic papillary renal cancer, but the combination showed promise for one subgroup, findings from the phase II CALYPSO trial showed. In the single-arm study, 12 of 41 patients (29%, 95% CI 16-46) had a confirmed […]
ICI-Related Myocarditis Deaths Down With Tailored Non-Corticosteroid Strategy
For immune checkpoint inhibitor (ICI)-associated myocarditis, increased vigilance of respiratory muscle failure and initiation of JAK‐STAT pathway inhibition led to a jump in patient survival at a Paris hospital. Based on 40 consecutive cancer patients admitted to Assistance Publique-Hôpitaux de Paris with confirmed ICI-associated myocarditis, the incidence of related death dropped from 60% during the […]
Add-On Olaparib Continues to Show Benefit in First-Line Treatment of mCRPC
SAN FRANCISCO — Adding the PARP inhibitor olaparib (Lynparza) to standard-of-care abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (mCRPC) extended median progression-free survival (PFS), according to final results of the double-blind phase III PROpel study reported here. There was also a trend toward an improvement in median overall survival (OS). At the […]
Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancer
SAN FRANCISCO — Treatment with the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) compared with enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer (mCRPC), the phase III TALAPRO-2 trial showed. Among 805 randomized patients, rPFS assessed by blinded independent central review was not reached in those who […]
Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO — Imaging-based progression-free survival (PFS) was significantly longer with the PARP inhibitor rucaparib (Rubraca) compared with physician’s choice of therapy in patients with BRCA or ATM-associated metastatic castration-resistant prostate cancer (CRPC), the phase III TRITON3 study showed. All patients in the study had already progressed after treatment with a second-generation androgen receptor-pathway inhibitor […]